15 Feb Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study
Anat Fisher, Jason D. Kim, Colin R. Dormuth CMAJ Open February 15, 2022 10 (1) E109-E118; DOI: 10.9778/cmajo.20200319 Abstract Background: In 2019, British Columbia’s public drug plan, PharmaCare, was the first in Canada to implement a nonmedical switching...